111 related articles for article (PubMed ID: 19963095)
1. Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.
Dancey JE
Semin Oncol; 2009 Dec; 36 Suppl 3():S1-2. PubMed ID: 19963095
[No Abstract] [Full Text] [Related]
2. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
3. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
Dancey JE; Curiel R; Purvis J
Semin Oncol; 2009 Dec; 36 Suppl 3():S46-58. PubMed ID: 19963100
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
5. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Boni JP; Hug B; Leister C; Sonnichsen D
Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA
Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
Bhatia S; Thompson JA
Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus, an inhibitor of mammalian target of rapamycin.
Rini BI
Clin Cancer Res; 2008 Mar; 14(5):1286-90. PubMed ID: 18316545
[No Abstract] [Full Text] [Related]
9. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
11. Molecule of the month. Temsirolimus.
Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
[No Abstract] [Full Text] [Related]
12. Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
Elit L
IDrugs; 2006 Sep; 9(9):636-44. PubMed ID: 16952072
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
[TBL] [Abstract][Full Text] [Related]
14. The potential role of mTOR inhibitors in non-small cell lung cancer.
Gridelli C; Maione P; Rossi A
Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
[TBL] [Abstract][Full Text] [Related]
15. [Everolimus (RAD001) and solid tumours: a 2008 summary].
Lévy A; Sauvin LA; Massard C; Soria JC
Bull Cancer; 2008 Dec; 95(12):1205-11. PubMed ID: 19091655
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
19. Evaluating the activity of temsirolimus in neuroendocrine cancer.
O'Donnell PH; Ratain MJ
Br J Cancer; 2007 Jan; 96(1):177; author reply 178-9. PubMed ID: 17164757
[No Abstract] [Full Text] [Related]
20. mTOR inhibitors.
Cohen E
Clin Adv Hematol Oncol; 2006 Jan; 4(1):38-9. PubMed ID: 16562369
[No Abstract] [Full Text] [Related]
[Next] [New Search]